[AmBisome, three challenges: Candida auris infection, central nervous system infection, and biofilm-associated...

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Invasive fungal infections pose significant diagnostic and therapeutic challenges.
• Candida auris is a multidrug-resistant yeast causing hospital outbreaks, particularly in intensive care units.
• Treatment of rare but severe invasive fungal infections, such as CNS or device-associated candidemia, is complicated by limited pharmacokinetic data.

Purpose of the Study:

• To review the challenges in diagnosing and treating invasive fungal infections.
• To highlight the specific difficulties posed by Candida auris, including its antifungal resistance.
• To emphasize the need for better understanding of antifungal pharmacokinetics and pharmacodynamics for optimizing treatment efficacy.

Main Methods:

• Literature review on invasive fungal infections, Candida auris, and antifungal therapies.
• Analysis of current treatment guidelines and recommendations.
• Discussion of pharmacokinetic and pharmacodynamic considerations for antifungal agents.

Main Results:

• Echinocandins are first-line agents for Candida auris infections, requiring susceptibility testing.
• Liposomal amphotericin B or isavuconazole may be added for refractory cases.
• Increased incidence of CNS and device-associated fungal infections with high mortality has been observed, particularly in immunocompromised patients.

Conclusions:

• Effective management of invasive fungal infections requires accurate diagnosis and appropriate antifungal therapy.
• Antifungal susceptibility testing is essential for guiding treatment of Candida auris infections.
• Further research into the pharmacokinetic and pharmacodynamic properties of antifungals is critical for improving treatment outcomes, especially for complex and severe infections.